Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 3/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | EBP | Q15125 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | GUSB | P08236 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19185652 | 1.00 | LTA4H (0.45) | LTA4HLMNAHRH3GNAI3GNAO1 | |
| SCHEMBL19185581 | 1.00 | LTA4H (0.45) | LTA4HLMNAHRH3GNAI3GNAO1 | |
| SCHEMBL19185641 | 1.00 | LTA4H (0.45) | LTA4HLMNAHRH3GNAI3GNAO1 | |
| SCHEMBL19185680 | 0.98 | LTA4H (0.44) | LTA4HLMNAHRH3GNAI3GNAO1 | |
| SCHEMBL22857557 | 0.98 | HRH3 (0.46) | LTA4HLMNAHRH3GNAI3GNAO1 | |
| SCHEMBL22857504 | 0.96 | HRH3 (0.45) | LTA4HLMNAHRH3GNAI3GNAO1 | |
| SCHEMBL25064562 | 0.96 | LMNA (0.43) | LTA4HLMNAHRH3GNAI3GNAO1 | |
| SCHEMBL21361903 | 0.94 | LTA4H (0.40) | LTA4HLMNAHRH3GNAI3GNAO1 | |
| SCHEMBL21725456 | 0.92 | HRH3 (0.41) | LTA4HHRH3GNAI3GNAO1GNAI1 | |
| SCHEMBL3229098 | 0.88 | HRH3 (0.48) | LTA4HLMNAHRH3GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292189-A1 | LIM KINASE INHIBITORS | VIRONGY, LLC | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292189-A1 | LIM KINASE INHIBITORS | LIMK1, LIMK2, LIMA1 | LTA4H 2475/4885LMNA 1096/4885HRH3 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.